A genomics research company here today announced the launch of an advanced RNA sequencing test, called 'PositiveSelect', for cancer, intended to aid oncologists select the best treatment for patients.
According to Positive Bioscience, the sequencing test is based on whole RNA sequencing and enhances the utility of comprehensive genomics profile manifold, bringing genomics test closer to clinical practice.
"PositiveSelect, India's first RNA sequencing test for cancer treatment is the most advanced genomics test for cancer based on whole RNA sequencing. It detects genomic alterations in 25,000 genes as compared to 4-5 genes through conventional testing," Positive Bioscience CEO Samarth Jain told reporters here.
He said that patients will be able to buy PositiveSelect, designed to provide oncologists with a clinically actionable report that can identify molecular alterations in a patient's tumour and match those alterations with relevant targeted therapies and clinical trials, starting March 1 this year.
"This is a comprehensive genomic solution for solid tumours like lung, breast, ovarian, prostrate as well as haematological cancers," he said.
"The test employs RNA sequencing to detect all classes of genomic alterations, including base pair substitutions, insertions and deletions, copy number alterations, rearrangements and gene fusions," he said.
Jain said governments can play a big role in taking the technology forward by making people aware so that there is a better chance of managing the disease.
"PositiveSelect will be available in all leading hospitals of the country on a prescription of oncologists," he added.